At a glance
ClinicalIndex Comparison RecordN/ACompleted· 526 enrolled
Drug / intervention
TheraSpheredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
In Brief
A clinical study evaluating TheraSphere for Unresectable Hepatocellular Carcinoma. Completed, enrolled 526 participants across 94 sites in 11 countries.
Detailed Summary
The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All patients receive the standard-of-care sorafenib with or without the addition of TheraSphere.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUnresectable Hepatocellular Carcinoma
CountriesBelgium, Canada, France, Germany, Italy, Netherlands, Singapore, South Korea, Spain, United Kingdom, United States
CollaboratorsBiocompatibles UK Ltd
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2012
First PostedMar 2012
Primary CompletionApr 2022
TodayJul 2026
First PostedMar 16, 2012
Enrollment StartMar 1, 2012
Primary CompletionApr 30, 2022
TodayJul 2, 2026
Enrollment to primary: 10.2 yearsPosted 14.3 years ago
Interventions
TheraSpheredevice
Yttrium 90 microspheres